Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 1:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 2,476 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HSCT Clear all

Conditions: Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Sphingolipidoses, Krabbe Disease, Wolman's Disease, Niemann-Pick Disease Type B, Niemann-Pick Disease, Type C
Interventions: Stem Cell Transplantation, Cyclophosphamide, Campath-1H, Busulfan; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 21 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hodgkin's Lymphoma
Interventions: Panobinostat, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Hematopoietic Stem Cell Transplantation, Hematologic Malignancy
Interventions: CliniMACS®; Device
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Graft vs Host Disease, Hematologic Neoplasms, Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions: Vorinostat, Tacrolimus, Methotrexate; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Neoplasms
Interventions: Th2/Tc2 Cells; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Stem Cell Transplantation, Hematologic Malignancy
Interventions: Expressive Helping, Factual Writing; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Hackensack, New Jersey

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma
Interventions: TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate; Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 7 Months to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, busulfan, cyclophosphamide, methotrexate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease, Thalassemia Major
Interventions: CliniMACS; Device
Lead sponsor: Timothy Olson; Other
Eligibility: 2 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wiskott-Aldrich Syndrome
Interventions: Hematopoietic stem cell transplantation, Miltenyi CliniMACS selection system, Fludarabine, Melphalan, Thiotepa; Procedure · Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: CMV Infection, Persistent CMV Viremia
Interventions: CMVpp65 Specific T-cells; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions: Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Fanconi's Anemia
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, fludarabine, methylprednisolone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 0 Years to 34 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic, Hematopoietic Stem Cell Transplant, Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, Adult T-Cell, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, in Remission, Cancer Remission
Interventions: TRX103; Biological
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Leukemia, Myeloid, Acute
Interventions: VCAR33; Biological
Lead sponsor: Vor Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: La Jolla, California • Stanford, California • Miami, Florida + 11 more

Conditions: Graft-versus-host Disease
Interventions: Cyclophosphamide, Abatacept, Bortezomib; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 14 Years to 100 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Leukemia, Myeloid, Acute
Interventions: AC220; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Duarte, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more

Conditions: Acute Myeloid Leukemia
Interventions: Aerobic Exercise, Resistance Training, Biospecimen Collection, Electronic Health Record Review, Survey Administration, Interview; Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Treatment-Related Cancer
Interventions: Acupressure for Children in Treatment for a Childhood Cancer; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years to 24 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions: First Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT, Cyclophosphamide, Methotrexate, Tacrolimus, Total Body Irradiation, Busulfan, Fludarabine, Second Allogeneic Bone Marrow Transplantation; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years to 55 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland • Oklahoma City, Oklahoma

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP; Drug · Procedure · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 4
States / cities: Miami, Florida • Houston, Texas • Seattle, Washington

Conditions: Total-body Irradiation, Hematopoietic Stem Cell Transplant
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 21 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Stem Cell Transplant
Interventions: Palliative Care Intervention, Standard Transplant Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Durham, North Carolina • Seattle, Washington

Conditions: Thrombotic Microangiopathy
Interventions: Ravulizumab, Best Supportive Care; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Up to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 8
States / cities: Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more

Search by objective public record fields.

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)

Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

Expressive Helping for Stem Cell Transplant Patients

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies

Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Tandem Auto-Allo Transplant for Lymphoma

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

Acupressure for Children in Treatment for a Childhood Cancer

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Radiation Biodosimetry in Children Undergoing Total Body Irradiation

Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation

Study of Ravulizumab in Pediatric Participants With HSCT-TMA